Astrazeneca ADR Stock
€71.50
Your prediction
Financial data and news for AstraZeneca
sharewise wants to provide you with the best news and tools for AstraZeneca, so we directly link to the best financial data sources.
Financials
News
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca PLC (NASDAQ: AZN) is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
Investors looking for stocks that can reliably outperform the broad market should have a look at the pharmaceutical industry. The tailwind pushing them forward is powerful. In the U.S., around
3 Market-Beating Stocks to Buy for Less Than $100
You don't have to look at top tech stocks to find good investments to buy and hold. There are many good stocks you can buy for less than $100 that are beating the market today and can continue to do
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
Industry insiders often have perspectives that are invaluable for investors to learn. In that vein, AstraZeneca's (NASDAQ: AZN) CEO, Pascal Soriot, recently made some interesting remarks during the
3 Surprisingly Underrated Stocks to Buy Right Now
The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely.
Three Motley Fool contributors think
AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q2 2024 Earnings CallJul 25, 2024, 6:45 a.m. ET
Operator
Source Fool.com
3 No-Brainer Stocks to Buy for Under $100 Right Now
A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.
We asked Three Motley Fool contributors to name no-brainer
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global
Forget Johnson & Johnson: Buy This Better Healthcare Stock Instead
Many healthcare investors look at Johnson & Johnson (NYSE: JNJ) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk.
The company continually runs into
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
AstraZeneca Plc (NASDAQ: AZN)Q1 2024 Earnings CallApr 25, 2024, 6:45 a.m. ET
Operator
Source Fool.com
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just